Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for renal and metabolic outcomes in cardiac surgery
NL-OMON26563Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of empagliflozin in acute kidney failure (AKF) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Plasma neutrophil gelatinase-associated lipocalin concentration. Planned start Sep 2021; status: not yet recruiting.
02
Drugs
empagliflozin
03
Conditions
acute kidney failure (AKF)
Beyond the preview
Go deeper on NL-OMON26563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON26563.